| Drug development |
| |
Article Title |
Author(s) |
Pages |
|
|
|
A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: An Innovative Therapies for Children with Cancer (ITCC) study
28 November 2011
Abstract: Aims: To determine the maximum tolerated dose, the recommended dose (RD) for phase II studies, dose-limiting toxicities and pharmacokinetics (PK) for plitidepsin administered as a 3-h intrav...
|
Birgit Geoerger,
Edward J. Estlin,
Isabelle Aerts,
Pamela Kearns,
Brenda Gibson,
Nadège Corradini,
François Doz,
Pilar Lardelli,
Bernardo De Miguel,
Arturo Soto,
Raquel Prados,
Gilles Vassal
et al.
|
289-296
|
|
| Breast cancer |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Physical activity in a German breast cancer patient cohort: One-year trends and characteristics associated with change in activity level
19 September 2011
Abstract: Background: Physical activity (PA) is increasingly discussed as concomitant therapy after breast cancer diagnosis and can add to the alleviation of therapy- and disease-related symptoms. The...
|
Christina Huy,
Martina E. Schmidt,
Alina Vrieling,
Jenny Chang-Claude,
Karen Steindorf
et al.
|
297-304
|
|
|
|
Tetraploidy in BRCA2 breast tumours
02 December 2011
Abstract: Tetraploidy and aneuploidy can be caused by cell division errors and are frequently observed in many human carcinomas. We have recently reported delayed cytokinesis in primary human fibrobla...
|
Asta Bjork Jonsdottir,
Olafur Andri Stefansson,
Johannes Bjornsson,
Jon G. Jonasson,
Helga M. Ogmundsdottir,
Jorunn E. Eyfjord
et al.
|
305-310
|
|
| Urologic oncology |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial
20 June 2011
Abstract: Background: In a double-blind, randomised phase III trial of advanced renal cell carcinoma patients, pazopanib 800mg QD (n=290) versus placebo (n=145) significantly prolonged progression-fre...
|
D. Cella,
A.S. Pickard,
M.S. Duh,
A. Guerin,
N. Mishagina,
L. Antràs,
M.P. Neary,
L. McCann,
R. Hodge,
C.N. Sternberg
et al.
|
311-323
|
|
|
|
An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
01 August 2011
Abstract: Background and objectives: The RECORD-1 trial established the clinical benefit of everolimus in patients with metastatic renal cell carcinoma (mRCC) after failure of initial vascular endothe...
|
Viktor Grünwald,
Pierre I. Karakiewicz,
Sevil E. Bavbek,
Kurt Miller,
Jean-Pascal Machiels,
Se-Hoon Lee,
James Larkin,
Petri Bono,
Sun Young Rha,
Daniel Castellano,
Christian U. Blank,
Jennifer J. Knox,
Robert Hawkins,
Oezlem Anak,
Marianne Rosamilia,
Jocelyn Booth,
Nicoletta Pirotta,
István Bodrogi,
on behalf of the REACT Study Group
et al.
|
324-332
|
|
|
|
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
03 January 2012
Abstract: Introduction: In the phase III RECORD-1 trial (ClinicalTrials.gov: NCT00410124), patients with metastatic renal cell carcinoma (mRCC) who progressed on previous vascular endothelial growth f...
|
E. Calvo,
B. Escudier,
R.J. Motzer,
S. Oudard,
T.E. Hutson,
C. Porta,
S. Bracarda,
V. Grünwald,
J.A. Thompson,
A. Ravaud,
D. Kim,
A. Panneerselvam,
O. Anak,
R.A. Figlin
et al.
|
333-339
|
|
|
|
The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis
29 December 2011
Abstract: Objective: We conducted a systematic review of the literature and performed a meta-analysis to determine the risk of developing skin rash and stomatitis among patients receiving temsirolimus...
|
Cristina Gomez-Fernandez,
Benjamin C. Garden,
Shenwong Wu,
Darren R. Feldman,
Mario E. Lacouture
et al.
|
340-346
|
|
| Melanoma |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Treatment influencing down-staging in EORTC Melanoma Group sentinel node histological protocol compared with complete step-sectioning: A national multicentre study
24 October 2011
Abstract: Aim: Metastasis size in melanoma sentinel lymph nodes (SLNs) is an emerging prognostic factor. Two European melanoma treatment trials include SLN metastasis diameters as inclusion criteria. ...
|
Rikke Riber-Hansen,
Nina Hastrup,
Ole Clemmensen,
Nille Behrendt,
Siri Klausen,
Mette Ramsing,
Eva Spaun,
Stephen Jacques Hamilton-Dutoit,
Torben Steiniche
et al.
|
347-352
|
|
| Neuro-oncology |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Central nervous system atypical teratoid rhabdoid tumours: The Canadian Paediatric Brain Tumour Consortium experience
24 October 2011
Abstract: Background: Atypical teratoid rhabdoid tumours (ATRT) are aggressive brain tumours mostly occurring in early childhood. Largest published series arise from registries and institutional exper...
|
L. Lafay-Cousin,
C. Hawkins,
A.S. Carret,
D. Johnston,
S. Zelcer,
B. Wilson,
N. Jabado,
K. Scheinemann,
D. Eisenstat,
C. Fryer,
A. Fleming,
C. Mpofu,
V. Larouche,
D. Strother,
E. Bouffet,
A. Huang
et al.
|
353-359
|
|
| Leukemia |
| |
Article Title |
Author(s) |
Pages |
|
|
|
The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: A joint analysis of five randomised trials on behalf of the EWALL
26 December 2011
Abstract: Background: Granulocyte-colony stimulating factor (G-CSF) is used to prevent febrile neutropenia and support intense chemotherapy. However, its impact on long-term outcome in oncological pat...
|
Sebastian Giebel,
Xavier Thomas,
Helene Hallbook,
Klaus Geissler,
Jean-Michel Boiron,
Francoise Huguet,
Elisabeth Koller,
Ulrich Jaeger,
Bengt Smedmyr,
Andrzej Hellmann,
Jerzy Holowiecki
et al.
|
360-367
|
|
| Quality of life |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Evolution of requests to hasten death among patients managed by palliative care teams in France: A multicentre cross-sectional survey (DemandE)
31 October 2011
Abstract: Background: Strongly marked ideological positions on the impact of palliative care and limited hard data plague the debate on physician-assisted death. Methods: A national cross-sectional st...
|
Edouard Ferrand,
Jean-François Dreyfus,
Mélanie Chastrusse,
Françoise Ellien,
François Lemaire,
Marc Fischler
et al.
|
368-376
|
|
|
|
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
17 November 2011
Abstract: Purpose: Patients with brain metastases (BM) rarely survive longer than 6months and are commonly excluded from clinical trials. We explored two combined modality regimens with novel agents w...
|
Gianfranco A. Pesce,
Dirk Klingbiel,
Karin Ribi,
Abderahim Zouhair,
Roger von Moos,
Marc Schlaeppi,
Clemens B. Caspar,
Natalie Fischer,
Sandro Anchisi,
Solange Peters,
Richard Cathomas,
Jürg Bernhard,
Nina M. Kotrubczik,
Giannicola D’Addario,
Christiane Pilop,
Damien C. Weber,
Stephan Bodis,
Miklos Pless,
Michael Mayer,
Roger Stupp
et al.
|
377-384
|
|
| Clinical trial design |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?
24 November 2011
Abstract: It can be difficult to identify endpoints that accurately reflect patient benefit in metastatic solid tumors. Overall survival (OS) is the gold standard although progression-free survival (P...
|
Eitan Amir,
Bostjan Seruga,
Ryan Kwong,
Ian F. Tannock,
Alberto Ocaña
et al.
|
385-388
|
|
| Basic and preclinical research |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Targeting Raf/MEK/ERK pathway in pituitary adenomas
28 November 2011
Abstract: Pituitary adenomas are the common neoplasms that cause mass effect and/or endocrine dysfunction. Studies in the pathogenesis and functional regulation of pituitary adenomas are mainly focuse...
|
Zhang Suojun,
Wan Feng,
Guo Dongsheng,
Lei Ting
|
389-395
|
|
|
|
The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy
09 December 2011
Abstract: Purpose: Regrowth of tumour cells between cycles of chemotherapy is a significant clinical problem. Treatment strategies where antiproliferative agents are used to inhibit tumour regrowth be...
|
Emma Hernlund,
Maria Hägg Olofsson,
Walid Fayad,
Mårten Fryknäs,
Karolina Lesiak-Mieczkowska,
Xiaonan Zhang,
Slavica Brnjic,
Vivien Schmidt,
Padraig D’Arcy,
Tobias Sjöblom,
Angelo De Milito,
Rolf Larsson,
Stig Linder
et al.
|
396-406
|
|
| Corrigendum |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Corrigendum to “Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis” [Eur J Cancer 47 (12) (2011) 1826–1836]
29 December 2011
Please note that the title of this article was expanded incorrectly during editing but unfortunately this error was not picked up during proof correction.
|
Stephen J. Clarke,
Sonia Yip,
Chris Brown,
Guy A. van Hazel,
David T. Ransom,
David Goldstein,
G. Mark Jeffrey,
Niall C. Tebbutt,
Martin Buck,
Raymond M. Lowenthal,
Amy Boland,
Val Gebski,
John Zalcberg,
R. John Simes,
on behalf of the Australasian Gastro-Intestinal Trials Group
et al.
|
407
|
|
